Larval Therapy: A Novel Treatment in Eliminating Methicillin-Resistant <i>Staphylococcus aureus</i> From Diabetic Foot Ulcers

Bowling, Frank L.; Salgami, Eleanna V.; Boulton, Andrew J.M.

doi:10.2337/dc06-2348

Cited by 95 publications

(46 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One previous study conducted in vivo also investigated the impact of loose larvae on the presence of MRSA in 13 patients with diabetic foot ulcers where MRSA was detected using MRSA-specific culturing techniques. 82 The study reports that MRSA was eliminated in 12 of the 13 wounds (92%) treated with loose larvae. However, the conclusions drawn from this study are limited because there was no control group.…”

Section: Mrsamentioning

confidence: 99%

See 1 more Smart Citation

VenUS II: a randomised controlled trial of larval therapy in the management of leg ulcers

Dumville

Worthy²,

Soares³

et al. 2009

Health Technol Assess

View full text Add to dashboard Cite

EA Nelson and DJ Torgerson on behalf of the VenUS II teamHow to obtain copies of this and other HTA programme reports An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable CD-ROM is also available (see below).Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for HealthResearch (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions f...

show abstract

Section: Mrsamentioning

confidence: 99%

“…A prospective case series used loose larvae to treated diabetic foot ulcers that had been colonised with MRSA for more than 3 weeks. 82 In total, 13 participants were recruited and treated with larval therapy. The study reports that MRSA was eliminated in all but one ulcer.…”

Section: Non-randomised Controlled Trial Evidencementioning

confidence: 99%

VenUS II: a randomised controlled trial of larval therapy in the management of leg ulcers

Dumville

Worthy²,

Soares³

et al. 2009

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Dette kan gi grunnlag for bruk av saerlig bredspektrede og kostbare antibiotika. Det er derfor interessant at man i en studie av 13 pasienter med MRSA-infiserte diabetiske fotsår oppnådde en fullstendig eradikasjon av stafylokokkene etter gjennomsnittlig tre larveapplikasjoner med en behandlingsvarighet på gjennomsnittlig 19 dager (26). Larveterapi bør derfor vaere et alternativ hvis konvensjonell behandling skulle feile.…”

Section: Figur 1 A) Nyklekkede Larver I Transportbeholder B) Sår På unclassified

Larveterapi i sårbehandling

Falch¹,

Weerd²,

Sundsfjord³

2009

Tidsskriftet

View full text Add to dashboard Cite

“…One review of over 1300 patients with infections caused by multi-resistant bacteria who were treated with specific bacteriophages reported full recovery in 85% and transient improvement in another 11% [54]. Yet another long-used form of biotherapy, maggot debridement, has also been found to be effective in eradicating MRSA colonization of diabetic foot ulcers [55]. Determining which of these old or new remedies may prove useful in treating DFIs will require proper controlled trials.…”

Section: Topical and Local Anti-microbialsmentioning

confidence: 99%

New developments in diagnosing and treating diabetic foot infections

Lipsky

2008

Diabetes Metab. Res. Rev.

View full text Add to dashboard Cite

Foot infections are common in persons with diabetes and are often the proximate cause of lower extremity amputation. There have been many publications in the past few years dealing with the appropriate ways to diagnose and treat diabetic foot infections. This review presents information gathered from a comprehensive, ongoing surveillance of the literature (published and abstracts) over the past 4 years. Prospective studies have now defined the epidemiology of diabetic foot infections, as well as methods to score and classify the wounds. Several recently published guidelines can assist clinicians in managing these infections. The etiologic agents of infection have been well-defined, and the prevalence of multi-drug-resistance pathogens is growing. Molecular methods offer great promise for quicker and more sensitive diagnosis of infection. New antimicrobial agents, both systemic and topical, as well as novel local treatments, have been shown to be effective in various studies. Improved methods of deploying older agents have added to the variety of treatment approaches now available. Several adjunctive treatments may benefit some patients but their role is as yet unclear. While there is much yet to learn about the most cost-effective ways to diagnose and treat diabetic foot infections the main effort is now to disseminate the available information and facilitate employing the evidence-based guideline recommendations.

show abstract

Larval Therapy: A Novel Treatment in Eliminating Methicillin-Resistant Staphylococcus aureus From Diabetic Foot Ulcers

Cited by 95 publications

References 10 publications

VenUS II: a randomised controlled trial of larval therapy in the management of leg ulcers

VenUS II: a randomised controlled trial of larval therapy in the management of leg ulcers

Larveterapi i sårbehandling

New developments in diagnosing and treating diabetic foot infections

Contact Info

Product

Resources

About